Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030787 | 0.82 | MC4R (0.38) | CYP2D6KCNH2 | |
| SCHEMBL16253366 | 0.81 | — | — | |
| SCHEMBL12469316 | 0.79 | FDPS (0.31) | — | |
| SCHEMBL19504453 | 0.78 | — | — | |
| SCHEMBL681912 | 0.76 | CHRNA7 (0.46) | CHRNA7KDM4EALDH1A1MAPTPKM | |
| SCHEMBL13290572 | 0.76 | CHRNA7 (0.46) | CHRNA7KDM4EALDH1A1MAPTPKM | |
| SCHEMBL13290580 | 0.76 | CHRNA7 (0.46) | CHRNA7KDM4EALDH1A1MAPTPKM | |
| SCHEMBL6660188 | 0.76 | CHRNA7 (0.46) | CHRNA7KDM4EALDH1A1MAPTPKM | |
| SCHEMBL13290568 | 0.76 | CHRNA7 (0.46) | CHRNA7KDM4EALDH1A1MAPTPKM | |
| SCHEMBL1106901 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800772-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800772-B2 | Therapeutic compounds | NQO1, HAVCR2, CCR5 | CHRNA7 4306/4885KDM4E 4115/4885ALDH1A1 321/4885 |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CHRNA7 4306/4885KDM4E 4115/4885ALDH1A1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.